DYADIC INTERNATIONAL SETS FIRESIDE CHAT ON POTENTIAL TRANSFORMATIVE PROTEIN TECHNOLOGY NEXT MONTH

KUALA LUMPUR, April 23 (Bernama) -- Biotechnology company, Dyadic International Inc (Dyadic) will host a fireside chat on May 4, focusing on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.

According to a statement, the moderated discussion will include Key Opinion Leaders namely, Alain Townsend, Ph.D.; Albert Osterhaus, P.V.M, Ph.D.; Cecil Nick; and, Dr Joris Vandeputte.

Dr Townsend is an Immunologist at the Weatherall Institute of Molecular Medicine, University of Oxford. Most of his work has been concerned with the presentation of Influenza antigens with class I molecules of the Major Histocompatibility complex.

Meanwhile, Professor Osterhaus has a long track record as scientific researcher and Principal Investigator of numerous major scientific projects. At Erasmus Medical Centre, he has run a diagnostic virology lab with more than 40 staff and a research virology lab with over 150 personnel.

In addition, Nick has particular expertise in monoclonals and biosimilars, having worked on over 20 such programmes, engaged in over 50 interactions and meetings with regulatory agencies including in the EU, US, Canada, and Australia.

On the other hand, International Alliance for Biological Standardization President, Dr Vandeputte has been involved in the complete value chain of vaccines: research, development, and production, regulatory and marketing.

The discussion will include regulatory considerations and advantages of the C1 platform; the efforts being undertaken by Dyadic to address the emerging SARS-CoV-2 variants; and, C1 platform’s potential for developing and manufacturing multi-valent COVID-19 and other subunit vaccines.

The conversation will be moderated by Dr David Bramhill, a veteran in the biotechnology industry with extensive experience using a wide array of protein production technologies.

More details at http://www.dyadic.com.

-- BERNAMA